jerzy
Uploaded by
28 SLIDES
492 VUES
290LIKES

Are Combinations the Solution: Perspectives on Combination Immunotherapy

DESCRIPTION

Are Combinations the Solution: Perspectives on Combination Immunotherapy.

1 / 28

Télécharger la présentation

Are Combinations the Solution: Perspectives on Combination Immunotherapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Are Combinations the Solution: Perspectives on Combination Immunotherapy

  2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

  3. Immunotherapy: Paradigm on the Rise

  4. MOA of Inhibitors on PD-1 Pathway

  5. FDA Approved PD-1/PD-L1 Inhibitors

  6. Toxicity With PD-1/PD-L1 Inhibitors

  7. Predictive Biomarkers Are Lacking

  8. PD-1 and CTLA-4 Inhibition in Melanoma

  9. CheckMate 069

  10. What About Other Tumors?

  11. CheckMate 012

  12. Durvalumab/Tremelimumab in NSCLC

  13. Toxicity in a Broader Population

  14. Immunotherapy Is Not Chemotherapy

  15. Immunotherapy/Immunotherapy Summary

  16. Chemoimmunotherapy

  17. KEYNOTE 021

  18. KEYNOTE 024

  19. Chemotherapy/Immunotherapy Summary

  20. Overcoming Challenges of Targeted Therapies

  21. PD-1/BRAF/MEK Inhibition in Melanoma

  22. PD-1/EGFR Inhibition in NSCLC

  23. TATTON Results: EGFR/PD-L1 Inhibition

  24. Is Immunotherapy the Right Approach?

  25. Mutational Load in Never Smokers

  26. Targeted Therapy/Immunotherapy Summary

  27. Overall Conclusions

  28. Abbreviations

More Related